These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 11392692)
21. Predictive value of primate models for AIDS. Haigwood NL AIDS Rev; 2004; 6(4):187-98. PubMed ID: 15700617 [TBL] [Abstract][Full Text] [Related]
22. AIDS vaccine 2001: looking to the future. Mitsuyasu RT Afr Health Sci; 2001 Dec; 1(2):99-105. PubMed ID: 12830816 [No Abstract] [Full Text] [Related]
23. Mighty mice. Scientists are still improving the humanized mouse model but are optimistic about its future role in evaluating AIDS vaccine candidates. von Bubnoff A IAVI Rep; 2008; 12(5):1, 8-11. PubMed ID: 20213868 [No Abstract] [Full Text] [Related]
24. Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines. Ferrantelli F; Cafaro A; Ensoli B Curr Opin Biotechnol; 2004 Dec; 15(6):543-56. PubMed ID: 15560981 [TBL] [Abstract][Full Text] [Related]
25. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection. Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321 [TBL] [Abstract][Full Text] [Related]
26. AIDS vaccines. The first shot in a highly targeted strategy. Cohen J Science; 2004 Nov; 306(5700):1276-7. PubMed ID: 15550634 [No Abstract] [Full Text] [Related]
27. AIDS vaccine: efficacy, safety and ethics. Veljkovic V; Veljkovic N; Glisic S; Ho MW Vaccine; 2008 Jun; 26(24):3072-7. PubMed ID: 18164521 [TBL] [Abstract][Full Text] [Related]
28. [BCG vaccination and development of an innovative vaccine for preventing vertical HIV transmission in Africa]. Pontrelli G; Colizzi V Ig Sanita Pubbl; 2006; 62(2):189-99. PubMed ID: 17206189 [TBL] [Abstract][Full Text] [Related]
29. Characterization of simian and human immunodeficiency chimeric viruses re-isolated from vaccinated macaque monkeys after challenge infection. Kwofie TB; Miura T; Ibuki K; Enose Y; Suzuki H; Ui M; Kuwata T; Hayami M Arch Virol; 2002 Jun; 147(6):1091-104. PubMed ID: 12111421 [TBL] [Abstract][Full Text] [Related]
30. HIV/AIDS vaccines: a need for new concepts? Girard MP; Bansal GP Int Rev Immunol; 2008; 27(6):447-71. PubMed ID: 19065351 [TBL] [Abstract][Full Text] [Related]
31. AIDS vaccine development and challenge viruses: getting real. Vlasak J; Ruprecht RM AIDS; 2006 Nov; 20(17):2135-40. PubMed ID: 17086052 [No Abstract] [Full Text] [Related]
32. HIV vaccine holds promise of global effectiveness. J Calif Dent Assoc; 2003 Jan; 31(1):13. PubMed ID: 12583445 [No Abstract] [Full Text] [Related]
34. AIDS vaccine efforts have followed long, bumpy road. AIDS Alert; 2001 May; 16(5):64-6, 54. PubMed ID: 11590782 [TBL] [Abstract][Full Text] [Related]
35. [PolyEnv, a new strategy in the development of anti-HIV vaccines]. Molina CN Sidahora; 2001 Oct; ():7-11. PubMed ID: 11776248 [No Abstract] [Full Text] [Related]
36. Adenoviruses as vectors for HIV vaccines. Gómez-Román VR; Robert-Guroff M AIDS Rev; 2003; 5(3):178-85. PubMed ID: 14598567 [TBL] [Abstract][Full Text] [Related]
37. A review of vaccine research and development: the human immunodeficiency virus (HIV). Girard MP; Osmanov SK; Kieny MP Vaccine; 2006 May; 24(19):4062-81. PubMed ID: 16530298 [TBL] [Abstract][Full Text] [Related]
39. Development of prophylactic AIDS vaccines: the current state of affairs. Hanke T Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467 [TBL] [Abstract][Full Text] [Related]